Severe Immune Thrombocytopenic Purpura Treated with Plasma Exchange


INTRODUCTION

Immune or idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by persistent thrombocytopenia, defined as a peripheral blood platelet count less than 100 $\times$ 10$^9$/L, due to autoantibody binding to platelet antigen(s) causing their premature destruction by the system, and in particular the spleen. There is an associated impaired platelet production and T cell–mediated effects. There is no “gold standard” test that can reliably establish the diagnosis. The essential elements for the diagnosis include an otherwise healthy individual who presents with isolated thrombocytopenia, an otherwise unremarkable peripheral smear, a physical examination that only shows evidence of bleeding consistent with the platelet count, and the exclusion of other causes of thrombocytopenia. Specialized assays in the diagnosis of ITP include assays for anti-platelet antibodies, thrombopoietin (TPO) assays, reticulated platelets etc. However, their use in a routine case of ITP is not established. ITP is classified by duration into newly diagnosed, persistent (3-12 months’ duration) and chronic (>12 months’ duration). In general, patients with platelet counts exceeding 30 $\times$ 10$^9$ per litre require no treatment unless they are undergoing any procedure likely to induce blood loss. Prednisolone (or prednisone) is the standard initial first-line therapy for ITP patients who require treatment. High dose dexamethasone or high dose intravenous methylprednisolone are used in severe, acute or refractory ITP. The alternative first line treatment of ITP include intravenous immunoglobulin (IVIG) or anti-D (WinRho). The mechanism of action of IVIg in ITP remains largely unknown but is believed to involve the blockade of Fc receptors on macrophages and other effectors of antibody-dependent cytotoxicity, the presence of anti-idiotypic antibodies in IVIg which block autoantibody binding to circulating platelets and immune suppression. Intravenous anti-D is appropriate for Rh(D) positive, non-splenectomized ITP patients and is avoided in autoimmune hemolytic anemia. Combining first-line therapies is appropriate in emergency settings eg steroid and IVIg. Other therapies that work rapidly include platelet transfusion, possibly in combination with IVIg, and emergency splenectomy. The second line therapies for persistent and chronic ITP include splenectomy, rituximab, danazol, TPO receptor agonists, vinca alkaloids, azathioprine, cyclosporin, cyclophosphamide, mycophenolate mofetil, dapsone etc, the choice of one agent over other depends on case to case basis.

ABSTRACT

Immune thrombocytopenic purpura (ITP) is a hematological disorder characterized by immunologically mediated destruction of platelets and absence of other causes of thrombocytopenia. Treatment is required when the low platelet count entails risk of serious bleeding. Steroid is the first line of management. Acute refractory ITP with very low platelet count is variably treated with high dose steroid, intravenous immunoglobulin (IVIg), anti D or emergency splenectomy. Here, we present a case of steroid resistant ITP with severe thrombocytopenia treated with plasma exchange and low dose IVIg who responded dramatically to the therapy with maintained platelet count till one month from the institution of therapy.

KEY WORDS

immune thrombocytopenic purpura, intravenous immunoglobulin, plasma exchange
CASE REPORT

A 70 years lady, married, housewife, was referred to our hospital with complaint of sudden onset of reddish rashes all over the body, epistaxis and gum bleeding. She had history of three episodes of small volume loose motions one day prior to the onset of present symptoms, however she did not have fever, pain abdomen, blood in stool, tenesmus, running nose, sore throat, myalgia or arthralgia. She did not have cough, shortness of breath or chest pain. Her bladder habits were normal. She did not have bony pain anywhere, no localized lumps or swelling; there was no history of Raynaud’s phenomenon, no jaundice in the past and no high risk behavior or exposure to blood or blood products prior to this episode. Her past history was significant for hypertension of two and half years’ duration for which she was regularly taking amlodipine 2.5 mg/day; apart from this she did not have exposure to any drugs, chemicals or radiation. Examination revealed pulse rate of 104/minute, blood pressure of 160/70 mmHg, petechiae, purpura and ecchymoses all over the body and evidence of gum and lower lip bleeding; rest of the examination was normal. She did not have anemia, lymphadenopathy, bony tenderness or hepatosplenomegaly.

She had first presented to a medical college hospital on the same day of onset of symptoms where the platelet count was 1,000/cmm with total leucocyte count 6,600/cmm, hemoglobin 9.2 gm% and normal peripheral smear. Her blood sugar, liver function tests and kidney function tests were normal. She was treated with Inj methyl prednisolone 1gm iv daily for three days from day one of presentation followed by oral prednisolone 60 mg/day. In the five days before she presented to our hospital she had received 20 units of platelet rich plasma (PRP) and two pints of fresh blood. Her blood group was O positive.

The first reports at our hospital revealed hemoglobin 7.6 gm%, leucocyte count 6200/cmm and platelet 4000/cmm, reticulocytes 2.5 %, normal peripheral smear otherwise, no evidence of fragmented RBCs, the biochemistry reports were normal except for indirect hyperbilirubinemia. Her HIV, HBsAg, anti HCV serology was negative, ANA, anti DsDNA and VDRL were negative, coomb’s test and anti-cardiolipin antibody tests were negative. Thyroid function test (TFT) was normal; bone marrow did not reveal malignant cells or any evidence of myelodysplastic syndrome. Steroid was continued first as oral prednisolone 60 mg/day followed by oral prednisolone 60 mg/day. In the five days before she presented to our hospital she had received 20 units of platelet rich plasma (PRP) and two pints of fresh blood. Her blood group was O positive.

From the above history and clinical examination the diagnosis of immune thrombocytopenic purpura (ITP) was made. The platelet count was persistently below 40,000/cmm. On the first day of she was given pantoprazole, amlodipine and prophylactic antibiotic coverage during TPE. She was discharged on prednisolone 40 mg/day. Three days after discharge, the platelet count was 240,000/cmm. Her platelet count was 312,000/cmm at three weeks after discharge.

DISCUSSION

In ITP, pathogenic autoantibodies bind platelets, resulting in accelerated platelet clearance. Targets of antiplatelet antibodies include glycoproteins Ib/IIIa and Ib/IX on the platelet membrane, although antibodies are demonstrable in only two-thirds of patients. Logically the therapy of ITP includes:

- Suppression of antibody production
- Suppression of clearance of the antibody bound platelets
- Removal of the main site of platelet destruction
- Stimulation of platelet production by the marrow
- Removal of the pathogenic autoantibodies or immune complexes.

This makes the rationale for the use of various first and second line therapies in ITP. To date there have been few randomized controlled trials conducted in the management of ITP. Treatment should be tailored to the individual patient.

Some two-thirds of patients will respond to prednisolone at 1 mg/ kg body weight per day, response appearing at 2–4 weeks. Our patient had acute and severe ITP, the platelet count was persistently below 4000/cmm at 10th day of methyl prednisolone with evidence of active mucocutaneous and UGI bleeding that necessitated emergent therapy. The prohibitively high cost of full dose IVlg in our set up and the low hemoglobin and indirect hyperbilirubinemia prompted us to consider plasma exchange as an alternative and cheaper rescue therapy for our patient. Though splenectomy has a durable response rate of over 60%, being an acute ITP, we ruled out the possibility of rescue emergency splenectomy in our patient. The increase in platelet count from 3000/cmm to 43,000/cmm after the first session of plasma exchange led us to give second exchange as well. These two exchanges
stabilized the platelet to safe level of above 30,000/cmm for a few days. The proven response to plasma exchange in our patient and the recommendation for IVIg in acute severe ITP made us use low dose IVIg at the completion of third TPE after which platelet level rose up and was sustained.

However, a few questions remain unanswered in this patient. First, since she had acute ITP, the disease could have been going into self-remission by the third week, though spontaneous remission in adult ITP is not common. Second, she had been continued on high dose of steroid throughout the period of TPE when the response of steroid might have started. However, the immediate rise in platelet count after first session of TPE largely ruled out this possibility. Third, the low dose IVIg after third exchange could have significantly contributed to the further rise in platelet count. Fourth and the most important of all whether the rise in platelet with aforementioned therapies in our patient will result in sustained maintenance of platelet in normal level is yet to be seen. However, we believe that TPE rescued this patient from life threatening low platelet count and could be useful in similar set of circumstances if judiciously applied.

TPE, though not proven to be of much usefulness in the management of chronic ITP, could be a potentially life-saving adjunctive approach in selected cases of acute severe ITP.

REFERENCES


